Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:58:05.338Z.
Calculation as of: 2026-10-06T19:58:05.338Z.
Quote observation: 2026-10-06T19:55:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c752279377b025acf72c3dd079155b3811244be546b74823e0a9f28be94cffb5
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nano-X Imaging Ltd. (NNOX) | $43.06M | N/A | N/A | N/A | N/A |
| Rapid Micro Biosystems, Inc. (RPID)vs › | $43.14M | N/A | N/A | N/A | N/A |
| CVRx, Inc. (CVRX)vs › | $42.99M | N/A | N/A | N/A | N/A |
| SANUWAVE Health Inc. (SNWV)vs › | $43.94M | 5.65 | 15.10 | 15.10 | 15.10 |
| Precipio, Inc. (PRPO)vs › | $42.07M | N/A | N/A | N/A | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $42.63M | N/A | 7.83 | 14.59 | 14.59 |
| DarioHealth Corp. (DRIO)vs › | $44.49M | 8.82 | 6.98 | 6.98 | 6.98 |
| Werewolf Therapeutics, Inc. (HOWL)vs › | $44.71M | N/A | N/A | N/A | N/A |
| Filana Therapeutics, Inc. (FLNA)vs › | $41.31M | N/A | N/A | N/A | N/A |
| Celularity Inc. (CELU)vs › | $45.73M | N/A | 11.46 | 11.53 | 11.53 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.62
Forward EPS (Est.)
$-1.26
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
